The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

The selected medications treat a range of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus ...

The U.S. government plans to lower Medicare costs for Botox by targeting its medical uses, marking a major shift in drug ...

Medicare is zeroing in on large, established drugs that generate steady cash, and that puts long-term pricing pressure on ...

Medicare selected Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.

CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...

The Centers for Medicare and Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Negotiated prices for Kisqali and Verzenio, which the agency said cost Medicare over $1 billion in a year, would become effective starting 2028.

CMS has announced that the new cycle of drug price negotiations by Medicare will include big-name drugs for diabetes and HIV/AIDS, as well as Botox injections. 1,2 The 15 high-cost prescription drugs ...

The U.S. plans to negotiate the prices of 15 more medications covered by Medicare, including two of Eli Lilly's top-selling drugs - though there were few surprises. The Centers for Medicare and ...

Tuesday's announcement is part of the Trump administration's efforts to reduce prescription drug costs for Americans, with ...